FORT WORTH, Texas, Nov. 11 Wound Management Technologies, Inc., (WNDM), announced today that its BioPharma Management Technologies Division will search for partners to aid in leveraging its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. The company intends to announce developments concerning advisory board appointments, research affiliations, and new partners as details emerge.
Advertisement
"Some of the most important developments in biotechnology and medical science have their origin at academic institutions and the startups that spring from them," stated Scott Haire, CEO of WNDM. "For example, Stem Cell Technology first came on the scene through the efforts of James Thomson in 1998 at the University of Wisconsin. James Thomson is the scientist who was the first to recover embryonic stem cells from human embryos through his work at the University Of Wisconsin School Of Medicine. The companies that are the first to capitalize on these types of advances gain a huge advantage for their shareholders."
Advertisement
WNDM has been conducting extended research studies on its existing products to seek out these types of advantages. It was recently observed at the University of Colorado and presented at a key worldwide symposium that WNDM's own CellerateRx has been shown to possibly influence biological factors important to wound healing beyond the obvious maintenance of the wound environment.
Divisions of major pharmaceutical companies have long recognized this and position themselves to work with startups to be able to capture emerging technologies that are the best-of-the-best. WNDM is following the lead of these industry leaders and through the BioPharma Division is positioned to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology, Genetic Engineering and Cancer Treatment markets. The recent acquisition of Resorbable Orthopedics LLC with its patented technologies, including a resorbable bone wax and a delivery system for orthopedic bone void fillers, was WNDM's first step to extend its product reach and incubator philosophy beyond Wound Care Innovation and its patented, activated form of collagen found in CellerateRX® products. Now, BioPharma Management Technologies is actively seeking additional partners with next generation technologies to add to our portfolio.
We encourage researchers, other companies and Universities to contact us with potential opportunities. For more details, potential Technology and Development Partners are urged to log onto our website at the division's page: http://www.woundmanagementtechnologies.com/wmt-research-and-marketing-collaboration.php . Follow the link named "Licensing Opportunities" to contact our research and development department for consideration.
For Wound Management Technologies Shareholder Information please call Ronnie Ambrose at 954-357-0614.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene (CELG) http://www.celgene.com, Geron (GERN) http://www.geron.com, and Human Genome Sciences (HGSI) http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit http://www.woundmanagementtechnologies.com or call our shareholder information department at 954-357-0614.
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
SOURCE Wound Management Technologies, Inc.
